surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PDF] Early-Onset Type 2 Diabetes

However, the pre-conception window offers a critical opportunity: patients can achieve meaningful weight loss and metabolic restoration during this preparation period, maximizing fertility potential before medication discontinuation

Growth hormone , which supports muscle maintenance and fat metabolism, is released predominantly during deep sleep cycles

For semaglutide, the earliest realistic timeline for generic injectable entry: 2029: Generic manufacturers begin bioequivalence studies (2 years before the 2031 method-of-use patent expiration) 2030: ANDA submissions filed 2031-2032: FDA approvals granted, market entry Generic oral semaglutide could follow a faster timeline because Teva's Paragraph IV strategy (using a different absorption enhancer) avoids the SNAC patent entirely: 2026: Teva completes bioequivalence studies (already done as of April 2026) 2026: ANDA submission 2027: FDA approval, market entry The gap between patent expiration and market entry is why patients should not expect immediate cost relief when patents expire

2 to 20 years: Boys Body mass index-for-age percentiles

The previous aircraft weight limitation was 6,000 pounds, with certification for up to six occupants